Carol Player’s experience highlights ongoing challenges faced by private health insurance holders seeking coverage for certain cancer treatments in the UK. Diagnosed with ocular melanoma in 2015 following persistent eye pain, Player underwent emergency eye removal. When the cancer spread to her liver in 2019, her consultant recommended chemosaturation therapy—a procedure delivering high-dose chemotherapy directly to the liver that has shown effectiveness in controlling tumors in clinical studies. Although this treatment is approved by the National Institute for Health and Care Excellence (NICE), it is not routinely available on the National Health Service (NHS).
Despite holding comprehensive cancer cover through Axa Health, Player’s insurer declined to fund chemosaturation therapy, citing limited usage and insufficient clinical evidence. Player was forced to raise over £200,000 through personal savings and fundraising to finance multiple rounds of treatment, which temporarily put her cancer into remission. The disease has since returned, and the £160,000 required for ongoing care remains uncovered by her insurer. She is now pursuing legal action, accusing Axa of an overly narrow and unlawful interpretation of its policy.
Player is not alone. Several others with Axa health insurance, including Lee Andrews from southeast London and Sam Franklin, who was diagnosed with multiple liver tumors, have faced similar denials for chemosaturation therapy. Both patients raised substantial sums independently to access treatment after their insurer refused coverage. Others, such as Richard Kersley, a long-term Axa customer diagnosed with aggressive brain cancer glioblastoma, were denied funding for treatment options like Optune, which may extend survival by several months. The treatment is not covered by Axa or Vitality but is reimbursed by other insurers such as Bupa, Aviva, and Allianz.
Patient advocacy groups and healthcare experts have criticized these refusals as potentially life-threatening and misleading to policyholders who believe their cancer cover is comprehensive. Jo Gumbs of Ocular Melanoma UK stated that Axa’s denial of claims has contributed to earlier deaths among affected customers. Legal representatives argue that some insurers apply inconsistent criteria and reject emerging therapies despite clinical validation and NICE approval.
Insurance brokers acknowledge that health insurance coverage for innovative or less common treatments remains highly variable across providers, creating disparities for patients based on their insurer and policy terms. Unlike auto or home insurance, rejected claims for health policies can mean loss of access to crucial, sometimes life-extending therapies. Consumers often face difficulty in anticipating what treatments will be covered, as policies frequently exclude therapies not widely adopted or lacking extensive trial data.
In response, Axa emphasized its commitment to reviewing new clinical evidence continuously and funding treatments once they meet established criteria. The insurer stated it supports thousands of cancer patients and aims to clarify coverage limits through detailed policy documents. However, critics contend that transparency alone is insufficient and urge insurers to ensure their marketed “comprehensive” cover genuinely encompasses effective treatments needed by patients.
As the number of private health insurance holders in the UK reaches record levels amid strain on NHS services, the gap between patient expectations and the realities of policy coverage has become increasingly apparent. The debate over the scope of cancer treatment funding through private insurance continues to raise critical questions about access, affordability, and the role of emerging therapies in life-threatening illnesses.